Everything looked better with tranexamic acid (TXA), and none of it was statistically significant. True, in a subgroup analysis of patients who actually had a head bleed on imaging—which, gee whiz, seems like an important subgroup!—28-day mortality was 27 percent for those who got placebo but 18 percent for those who got a large TXA bolus of 2 g.

The p=0.03, so this is statistically significant, suggesting we could save the life of one in 11 head bleeds.

But we serious doctors disdain subgroups.

The authors only mention this finding in the fine print.

Their abstract one-liner? Prehospital TXA “did not significantly improve 6-month neurologic outcome.”

Read More